Core Insights - NeurAxis, Inc. announced that the American Medical Association has established a new CPT Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures, effective January 1, 2026, which is a significant milestone for the company [1][2] - The company's IB-Stim technology is FDA-cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 11-18, addressing a gap in available treatments for this demographic [1][3] - NeurAxis is focused on advancing neuromodulation therapies and is conducting additional clinical trials for PENFS in various pediatric and adult conditions with large unmet healthcare needs [3] Company Overview - NeurAxis, Inc. specializes in medical technology aimed at neuromodulation therapies for chronic and debilitating conditions in both children and adults [3] - The company is dedicated to leveraging evidence-based medicine to promote the adoption of its proprietary IB-Stim therapy within the medical, scientific, and patient communities [3] - There are currently no FDA-approved drug therapies for children suffering from abdominal pain-related disorders of gut-brain interaction, highlighting the importance of NeurAxis's offerings [1]
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation